Off-Label Reprints Defended By AMA In Comments To FDA
Executive Summary
Physicians are more likely to read off-label drug information with a critical eye when it is disseminated by the drug's sponsor rather than obtained independently, the American Medical Association maintained in comments to FDA in support of off-label reprint dissemination